Abstract
The pharmacological indications for acetyl salicylic acid have been on the increase over the years. It was initially indicated for the management of inflammation but its use as a cardioprotective agent is now more prominent. However, one of the major drawbacks of this drug is gastric irritation and bleeding which could lead to ulcer, anemia and several medical complications. These drawbacks are attributable to salicylic acid residue in acetyl salicylic acid. The determination of salicylic acid residue in acetylsalicylic acid (ASA) tablets was carried out using a spectrophotometric method.
 Twenty one formulations of acetylsalicylic acid (ASA) tablets were assayed. From the results, 71.43% of the formulations failed to meet up the British pharmacopoeia standard of 0.75% limit of free salicylic acid in acetylsalicylic acid tablets. This work highlights the need for regulatory agencies to routinely determine the level of free salicylic acid in acetylsalicylic acid formulations to ensure that they conform to pharmacopoeia standard
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
